Dermata Therapeutics announces $3.4 million private placement

Dermata Therapeutics, Inc. (Nasdaq: DRMA) said on August 17, 2026 that it had signed definitive agreements to sell common stock, series E warrants and short-term series F warrants in a private placement priced at-the-market under Nasdaq rules. The deal covers 2,293,608 shares of common stock, or pre-funded warrants in place of shares, along with matching series E and series F warrants to buy up to 2,293,608 shares each, priced at $1.46 per share and warrant unit.¹

The series E and series F warrants carry an exercise price of $1.46 and become exercisable once stockholders approve the share issuance underlying them, with the series E warrants expiring five years after that approval date and the series F warrants expiring twenty-four months after it.¹ Closing is expected on or about August 18, 2026, pending customary conditions.¹

Company insiders, including the CEO, CFO and a member of management, are participating at a slightly higher price of $1.47 per share and warrant, with matching $1.47 warrant exercise pricing, in line with Nasdaq rules.¹

Gross proceeds are expected to be about $3.4 million before expenses, with up to roughly $6.7 million in additional proceeds possible if the series E and F warrants are fully exercised for cash.¹ The company cautioned there is no guarantee the warrants will be exercised or that it will collect that additional cash.¹

Dermata said net proceeds would go toward general corporate purposes, including consumer research, prelaunch and launch work for its new direct-to-consumer product, potential acquisitions or licensing tied to its technologies, and working capital.¹

Under a registration rights agreement, Dermata agreed to file a resale registration statement covering the securities.¹ The company described itself as pivoting from pharmaceutical development toward direct-to-consumer skincare, centered on a skin renewal treatment using its Bioneedle technology, with its first product launch expected August 25, 2026.¹